Literature DB >> 23707942

Epigenetic regulation of microRNA expression in renal cell carcinoma.

Miriam Schiffgen1, Doris H Schmidt, Alexander von Rücker, Stefan C Müller, Jörg Ellinger.   

Abstract

The underlying mechanisms of microRNA deregulation in cancer cells include epigenetic modifications, which play a crucial role in carcinogenesis. We demonstrate that numerous microRNAs are induced in renal cell carcinoma cell lines after treatment with inhibitors of the DNA-methyltransferase (5-aza-2'-deoxycytidine) and the histone-deacetylase (suberoylanilide hydroxamic acid). We provide evidence that enrichment of H3 and H3K18 acetylation at the miR-9 promoter is causative for re-expression, while DNA hypermethylation remains unchanged. Our experiments show that the treatment with the epigenetic drugs causes re-expression of silenced microRNAs with putative tumor suppressive function in ccRCC cell lines.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23707942     DOI: 10.1016/j.bbrc.2013.05.061

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Methylation and expression levels of microRNA-23b/-24-1/-27b, microRNA-30c-1/-30e, microRNA-301a and let-7g are dysregulated in clear cell renal cell carcinoma.

Authors:  I Gilyazova; E Ivanova; G Gilyazova; I Sultanov; A Izmailov; R Safiullin; V Pavlov; E Khusnutdinova
Journal:  Mol Biol Rep       Date:  2021-07-24       Impact factor: 2.316

Review 2.  MicroRNAs in renal cell carcinoma: a systematic review of clinical implications (Review).

Authors:  Ming Li; Ying Wang; Yongsheng Song; Renge Bu; Bo Yin; Xiang Fei; Qizhen Guo; Bin Wu
Journal:  Oncol Rep       Date:  2015-02-13       Impact factor: 3.906

3.  CAPE increases the expression of SOD3 through epigenetics in human retinal endothelial cells.

Authors:  Atsuko Ohashi; Hiroyuki Yasuda; Tetsuro Kamiya; Hirokazu Hara; Tetsuo Adachi
Journal:  J Clin Biochem Nutr       Date:  2017-06-20       Impact factor: 3.114

4.  Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.

Authors:  Roberto Pili; Glenn Liu; Sreenivasulu Chintala; Hendrick Verheul; Shabnam Rehman; Kristopher Attwood; Martin A Lodge; Richard Wahl; James I Martin; Kiersten Marie Miles; Silvia Paesante; Remi Adelaiye; Alejandro Godoy; Serina King; James Zwiebel; Michael A Carducci
Journal:  Br J Cancer       Date:  2017-02-21       Impact factor: 7.640

Review 5.  The role of epigenetics in kidney malignancies.

Authors:  Alfredo Harb-De la Rosa; Matthew Acker; Sanjaya Swain; Murugesan Manoharan
Journal:  Cent European J Urol       Date:  2015-04-20

6.  miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma.

Authors:  Bernhard Ralla; Jonas Busch; Anne Flörcken; Jörg Westermann; Zhongwei Zhao; Ergin Kilic; Sabine Weickmann; Monika Jung; Annika Fendler; Klaus Jung
Journal:  Cancers (Basel)       Date:  2018-09-10       Impact factor: 6.639

Review 7.  Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors.

Authors:  Pierre Autin; Christophe Blanquart; Delphine Fradin
Journal:  Cancers (Basel)       Date:  2019-10-10       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.